For companies like GSS, it seems that a rule of thumb applies where the global revenue tends to be 20x Australian revenue. With the current product maturity level, this implies a prospective global revenue of ~100m if FDA approval is forthcoming. That would put a real rocket under the market.
For companies like GSS, it seems that a rule of thumb applies...
Add to My Watchlist
What is My Watchlist?
